Comparison - NAMS - NASDAQ

Weiss Ratings	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Rating	D
Reward Index	Very Weak
Risk Index	Weak
Risk Grade	D
Reward Grade	E

Rating Factors	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Dividend Index	--
Growth Index	Very Weak
Efficiency Index	Very Weak
Solvency Index	Excellent
Total Return Index	Fair
Volatility Index	Weak

Beta / Standard Deviation	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Beta	0.98

Price History	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
7-Day Total Return	-16.97%
30-Day Total Return	-28.00%
60-Day Total Return	-37.00%
90-Day Total Return	-23.83%
Year to Date Total Return	-41.76%
1-Year Total Return	-24.13%
2-Year Total Return	11.83%
3-Year Total Return	53.50%
5-Year Total Return	--
52-Week High % Change	-45.40%
52-Week Low % Change	5.97%

Price	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
52-Week High Price	$27.29
52-Week Low Price	$14.06
52-Week Low Price (Date)	Apr 07, 2025
52-Week High Price (Date)	Dec 11, 2024

Valuation	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Market Cap	1.64B
Enterprise Value	802.54M
Price/Earnings (TTM)	--
Earnings Per Share (TTM)	-3.64
Earnings Per Share Growth	68.87%
Price/Earnings To Growth	--
Price/Sales (TTM)	32.52
Price/Book (Q)	2.13
Enterprise Value/Revenue (TTM)	17.61
Price	$15.12
Enterprise Value/EBITDA (TTM)	-4.56
Enterprise Value/EBIT	-4.55
Market Cap Category	Small Cap

Dividends and Shares	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Shares Outstanding	99.43M
Dividend Yield	--
Div. Per Share (Most Recent)	--
Dividend Per Share (TTM)	--
Payout Ratio (TTM)	--
Dividend Per Share (Most Recent)	--

Company Info	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Phone Number	31 35 206 2971
Address	--
Website	www.newamsterdampharma.com
Country	Netherlands
Year Founded	--

Profitability	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Operating Margin (TTM)	-386.91%
Profit Margin	-530.25%

Management Effectiveness	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Return on Assets	-18.19%
Return on Equity	--

Income Statement	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Revenue (TTM)	45.56M
Total Revenue (TTM)	45.56M
Revenue Per Share	$0.46
Gross Profit (TTM)	45.56M
EBITDA (TTM)	-176.18M
EBIT (TTM)	-176.29M
Net Income (TTM)	-241.60M
Net Income Avl. to Common (TTM)	-241.60M
Total Revenue Growth (Q YOY)	1,490.54%
Earnings Growth (Q YOY)	-86.23%
EPS Diluted (TTM)	-3.64
EPS Diluted Growth (Q YOY)	-54.47%

Balance Sheet	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Cash and Short-Term Inv. (Q)	834.19M
Cash Per Share (Q)	$8.39
Total Current Assets (Q)	863.41M
Total Preferred Equity (Q)	--
Total Equity (Q)	757.50M
Current Ratio (Q)	8.075
Book Value Per Share (Q)	$7.01
Total Assets (Q)	864.62M
Total Current Liabilities (Q)	106.92M
Total Debt (Q)	448.00K
Total Liabilities (Q)	107.12M
Total Common Equity (Q)	757.50M

Cash Flow	NAMS - NASDAQ	Click to Compare	Click to Compare	Click to Compare
Cash from Investing (TTM)	-62.85M
Cash from Financing (TTM)	659.51M
Net Change in Cash (TTM)	431.29M
Levered Free Cash Flow (TTM)	-25.78M
Cash from Operations (TTM)	-158.56M